Table 4

Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR

David Bonsall, William F. Gregory, Camilla L.C. Ip, Sharyne Donfield, James Iles, M. Azim Ansari, Paolo Piazza, Amy Trebes, Anthony Brown, John Frater, Oliver G. Pybus, Phillip Goulder, Paul Klenerman, Rory Bowden, Edward D. Gomperts, Eleanor Barnes, Amit Kapoor, Colin P. Sharp, and Peter Simmonds

Author affiliations: University of Oxford, Oxford, UK (D. Bonsall, C.L.C. Ip, J. Iles, M.A. Ansari, P. Piazza, A. Trebes, A. Brown, J. Frater, O.G. Pybus, P. Goulder, P. Klenerman, R. Bowden, E. Barnes, P. Simmonds); University of Edinburgh Easter Bush, Edinburgh, Scotland, UK (W.F. Gregory, C.P. Sharp); Rho, Inc., Chapel Hill, North Carolina, USA (S. Donfield); The Childrens' Hospital, Los Angeles, California, USA (E.D. Gomperts); The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA (A. Kapoor)

Main Article

Validation of human pegivirus detection in plasma samples by using PCR*

No. samples	Metagenomic screen results†		Primers, no. positive
No. samples	HHpgV-1	HPgV	Group 2	ak1/ak2‡	Group 1
2	+	–	2	2	0
1	+/–	–	0	0	0
10	–	+	0	0	10
10	–	–	0	0	0
*HPgV, human pegivirus; HHpgV, human hepegivirus; +, positive; –, negative. †Virus status as determined by bioinformatic screening. ‡Nonstructural 3 genes as previously described (6).

Main Article

Page created: March 15, 2016

Page updated: March 15, 2016

Page reviewed: March 15, 2016

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.